Based on the results shown above and given the possible clinical relevance of strategies able to modify the molecular ratio CRBN/MEIS2 and improve anti-MM activity of IMiDs, we investigated the ability of BETi to regulate the expression of MEIS2 in MM cells. This evidence concerns the gene CRBN and Miyoshi myopathy.